$BOLT
Bolt Biotherapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023039061 Filed on August 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $2.528M $1.433M $1.393M
YoY Change 19.7% 2.87%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.760M $5.621M $5.532M
YoY Change 5.01% 1.61% 36.46%
% of Gross Profit
Research & Development $14.95M $15.64M $18.92M
YoY Change -21.2% -17.32% -3.99%
% of Gross Profit
Depreciation & Amortization $500.0K $400.0K $400.0K
YoY Change 25.0% 0.0% 100.0%
% of Gross Profit
Operating Expenses $20.71M $21.27M $24.45M
YoY Change -15.32% -13.03% 2.91%
Operating Profit -$18.18M -$19.83M -$23.06M
YoY Change -18.63% -13.99% -2.95%
Interest Expense $1.930M $1.775M $395.0K
YoY Change 228.79% 349.37% 124.43%
% of Operating Profit
Other Income/Expense, Net $1.926M $1.775M $395.0K
YoY Change 228.11% 349.37% 124.43%
Pretax Income -$16.26M -$18.06M -$22.66M
YoY Change -25.27% -20.33% -3.91%
Income Tax
% Of Pretax Income
Net Earnings -$16.26M -$18.06M -$22.66M
YoY Change -25.29% -20.33% -3.91%
Net Earnings / Revenue -643.08% -1260.08% -1626.99%
Basic Earnings Per Share -$0.43 -$0.48 -$0.61
Diluted Earnings Per Share -$0.43 -$0.48 -$607.7K
COMMON SHARES
Basic Shares Outstanding 37.95M 37.81M 37.52M
Diluted Shares Outstanding 37.87M 37.75M 37.29M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $119.7M $125.9M $176.3M
YoY Change -30.05% -28.62% -28.02%
Cash & Equivalents $9.160M $13.45M $22.62M
Short-Term Investments $110.6M $112.4M $153.7M
Other Short-Term Assets $5.700M $4.802M $4.927M
YoY Change 54.22% -2.54% 55.77%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $125.5M $130.7M $181.3M
YoY Change -28.23% -27.91% -26.95%
LONG-TERM ASSETS
Property, Plant & Equipment $5.266M $5.609M $6.525M
YoY Change -23.74% -14.04% 43.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $21.60M $31.22M $47.28M
YoY Change -43.8% -33.97% -28.29%
Other Assets $1.342M $1.012M $997.0K
YoY Change 34.2% 1.5% -59.0%
Total Long-Term Assets $49.89M $60.03M $78.98M
YoY Change -29.41% -23.99% -20.17%
TOTAL ASSETS
Total Short-Term Assets $125.5M $130.7M $181.3M
Total Long-Term Assets $49.89M $60.03M $78.98M
Total Assets $175.4M $190.7M $260.2M
YoY Change -28.57% -26.72% -25.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.682M $3.436M $3.362M
YoY Change -3.81% 2.2% 108.3%
Accrued Expenses $13.10M $12.50M $11.75M
YoY Change -23.74% 6.34% -11.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.75M $17.62M $18.62M
YoY Change -22.43% -5.39% -3.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $43.00K $43.00K $200.0K
YoY Change -78.5% -78.5% -99.37%
Total Long-Term Liabilities $43.00K $43.00K $200.0K
YoY Change -78.5% -78.5% -99.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.75M $17.62M $18.62M
Total Long-Term Liabilities $43.00K $43.00K $200.0K
Total Liabilities $47.10M $48.56M $52.27M
YoY Change -17.46% -7.09% 2.13%
SHAREHOLDERS EQUITY
Retained Earnings -$346.4M -$330.1M -$253.3M
YoY Change 25.92% 30.3% 61.94%
Common Stock $474.8M $472.5M $463.1M
YoY Change 2.06% 2.03% 2.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $128.3M $142.1M $208.0M
YoY Change
Total Liabilities & Shareholders Equity $175.4M $190.7M $260.2M
YoY Change -28.57% -26.72% -25.02%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$16.26M -$18.06M -$22.66M
YoY Change -25.29% -20.33% -3.91%
Depreciation, Depletion And Amortization $500.0K $400.0K $400.0K
YoY Change 25.0% 0.0% 100.0%
Cash From Operating Activities -$16.75M -$15.11M -$20.79M
YoY Change 24.53% -27.3% 421.63%
INVESTING ACTIVITIES
Capital Expenditures $160.0K $32.00K -$429.0K
YoY Change -121.77% -107.46% -38.8%
Acquisitions
YoY Change
Other Investing Activities $12.82M $13.61M -$439.0K
YoY Change 486.73% -3200.68% -99.04%
Cash From Investing Activities $12.66M $13.58M -$868.0K
YoY Change 773.1% -1664.52% -98.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 147.0K 252.0K
YoY Change -41.67% -98.12%
NET CHANGE
Cash From Operating Activities -16.75M -15.11M -20.79M
Cash From Investing Activities 12.66M 13.58M -868.0K
Cash From Financing Activities 0.000 147.0K 252.0K
Net Change In Cash -4.090M -1.385M -21.40M
YoY Change -65.92% -93.53% -42.43%
FREE CASH FLOW
Cash From Operating Activities -$16.75M -$15.11M -$20.79M
Capital Expenditures $160.0K $32.00K -$429.0K
Free Cash Flow -$16.91M -$15.14M -$20.36M
YoY Change 32.98% -25.61% 519.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001641281
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39988
dei Entity Registrant Name
EntityRegistrantName
Bolt Biotherapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2804636
dei Entity Address Address Line1
EntityAddressAddressLine1
900 Chesapeake
dei Entity Address Address Line2
EntityAddressAddressLine2
Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94063
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
665-9295
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value
dei Trading Symbol
TradingSymbol
BOLT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37950986
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13451000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9244000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
112415000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
159644000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4802000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3858000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
130668000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
172746000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5609000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37797902
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
472485000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
467513000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6453000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20622000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22072000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1565000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1565000
CY2023Q2 us-gaap Long Term Investments
LongTermInvestments
31220000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
23943000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1012000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1028000
CY2023Q2 us-gaap Assets
Assets
190696000
CY2022Q4 us-gaap Assets
Assets
227807000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3436000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3594000
CY2023Q2 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9916000
CY2022Q4 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
15140000
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1685000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1993000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2581000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2391000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17618000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23118000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18891000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20220000
CY2023Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
12012000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
12921000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42000
CY2023Q2 us-gaap Liabilities
Liabilities
48564000
CY2022Q4 us-gaap Liabilities
Liabilities
56301000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37950986
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37950986
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37797902
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-229000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-919000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-330125000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-295088000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
142132000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
171506000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
190696000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
227807000
CY2023Q2 us-gaap Revenues
Revenues
1433000
CY2022Q2 us-gaap Revenues
Revenues
1393000
us-gaap Revenues
Revenues
3259000
us-gaap Revenues
Revenues
2206000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15644000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18920000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30269000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37305000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5621000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5532000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11237000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11836000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
21265000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
24452000
us-gaap Operating Expenses
OperatingExpenses
41506000
us-gaap Operating Expenses
OperatingExpenses
49141000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19832000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23059000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38247000
us-gaap Operating Income Loss
OperatingIncomeLoss
-46935000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
1775000
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
395000
us-gaap Investment Income Net
InvestmentIncomeNet
3210000
us-gaap Investment Income Net
InvestmentIncomeNet
593000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1775000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
395000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3210000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
593000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18057000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22664000
us-gaap Net Income Loss
NetIncomeLoss
-35037000
us-gaap Net Income Loss
NetIncomeLoss
-46342000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-407000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
690000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1482000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18051000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23071000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34347000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47824000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37750393
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37750393
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37293557
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37293557
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37717391
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37717391
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37211174
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37211174
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
157686000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
141000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2350000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18057000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
142132000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
228394000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
224000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2022Q2 bolt Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
2000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2391000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-407000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22664000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
207968000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
171506000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
141000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4826000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
690000
us-gaap Net Income Loss
NetIncomeLoss
-35037000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
142132000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
250119000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
224000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
135000
bolt Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
4000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5310000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1482000
us-gaap Net Income Loss
NetIncomeLoss
-46342000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
207968000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
98000
bolt Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
102000
us-gaap Profit Loss
ProfitLoss
-35037000
us-gaap Profit Loss
ProfitLoss
-46342000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
925000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
765000
us-gaap Share Based Compensation
ShareBasedCompensation
4826000
us-gaap Share Based Compensation
ShareBasedCompensation
5310000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1964000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-693000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1450000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1838000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
928000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1941000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5428000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3087000
bolt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1139000
bolt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1461000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1217000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-870000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-6000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38511000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45101000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1034000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
96524000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
107433000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
139130000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
148444000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42571000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
39977000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
147000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
359000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
147000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
359000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4207000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4765000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10809000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28948000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15016000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24183000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13451000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22618000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1565000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1565000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15016000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24183000
bolt Vesting Of Exercised Options
VestingOfExercisedOptions
4000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
46000
bolt Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
102000
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
157100000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-330100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, stock-based compensation and accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
us-gaap Financing Receivable Allowance For Credit Losses Policy For Uncollectible Amounts
FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Allowance for Credit Losses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For available-for-sale securities in an unrealized loss position, the Company first assesses whether it intends to sell, or if it is more likely than not that the Company will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For available-for-sale securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the severity of the impairment, any changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive income (loss) on the statements of operations and comprehensive loss.<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company elected the practical expedient to exclude the applicable accrued interest from both the fair value and amortized costs basis of its available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded within cash and cash equivalents on the Company's condensed balance sheets. The Company's accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which the Company considers to be in the period in which it determines the accrued interest will not be collected by the Company.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. As of June 30, 2023 and December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, most of the Company’s funds were invested with a registered investment manager and custodied at one financial institution, with operating cash kept at a separate financial institution, and account balances may at times exceed federally insured limits. Management believes that the Company is not subject to unusual or significant credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
143865000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
26000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
256000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
143635000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
184507000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
932000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
183587000
CY2023Q2 us-gaap Impaired Financing Receivable Related Allowance
ImpairedFinancingReceivableRelatedAllowance
0
CY2023Q2 bolt Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Estimated Fair Valued
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsEstimatedFairValued
48433000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
24000
CY2023Q2 bolt Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Estimated Fair Value
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerEstimatedFairValue
63036000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
232000
CY2023Q2 bolt Debt Securities Available For Sale Unrealized Loss Position Estimated Fair Value
DebtSecuritiesAvailableForSaleUnrealizedLossPositionEstimatedFairValue
111469000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
256000
CY2022Q4 bolt Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Estimated Fair Valued
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsEstimatedFairValued
24880000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
65000
CY2022Q4 bolt Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Estimated Fair Value
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerEstimatedFairValue
102536000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
867000
CY2022Q4 bolt Debt Securities Available For Sale Unrealized Loss Position Estimated Fair Value
DebtSecuritiesAvailableForSaleUnrealizedLossPositionEstimatedFairValue
127416000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
932000
CY2023Q2 bolt Accrued Interest Receivable On Available For Sale Securities
AccruedInterestReceivableOnAvailableForSaleSecurities
300000
CY2022Q4 bolt Accrued Interest Receivable On Available For Sale Securities
AccruedInterestReceivableOnAvailableForSaleSecurities
500000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10449000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10368000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4840000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3915000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5609000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6453000
CY2023Q2 us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
900000
CY2022Q2 us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
800000
CY2023Q2 bolt Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
5516000
CY2022Q4 bolt Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
9373000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3574000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4804000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
826000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
963000
CY2023Q2 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9916000
CY2022Q4 bolt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
15140000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4600000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M6D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.110
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y4M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.110
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1119000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1041000
us-gaap Operating Lease Cost
OperatingLeaseCost
2239000
us-gaap Operating Lease Cost
OperatingLeaseCost
2175000
us-gaap Operating Lease Payments
OperatingLeasePayments
2332000
us-gaap Operating Lease Payments
OperatingLeasePayments
2289000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2393000
CY2023Q2 bolt Lessee Operating Sublease Income Receivable Remainder Of Fiscal Year
LesseeOperatingSubleaseIncomeReceivableRemainderOfFiscalYear
354000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4886000
CY2023Q2 bolt Lessee Operating Sublease Income Due Next Twelve Months
LesseeOperatingSubleaseIncomeDueNextTwelveMonths
540000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4340000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3484000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3602000
CY2023Q2 bolt Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
13238000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
31943000
CY2023Q2 bolt Lessee Operating Sublease Income
LesseeOperatingSubleaseIncome
894000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10471000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
21472000
us-gaap Sublease Income
SubleaseIncome
894000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2350000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2391000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4826000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5310000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18057000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22664000
us-gaap Net Income Loss
NetIncomeLoss
-35037000
us-gaap Net Income Loss
NetIncomeLoss
-46342000
CY2023Q2 bolt Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
37851141
CY2022Q2 bolt Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
37517136
bolt Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
37826508
bolt Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
37475640
CY2023Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
100748
CY2022Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
223579
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
109117
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
264466
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37750393
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37750393
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37293557
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37293557
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37717391
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37717391
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37211174
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37211174
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10884085
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7929023
bolt Rule10 B51 Arr Trmntd Flag
Rule10B51ArrTrmntdFlag
true
bolt Trd Arr Ind Name
TrdArrIndName
Edith A. Perez, M.D
bolt Trd Arr Ind Title
TrdArrIndTitle
Chief Medical Officer
bolt Rule10 B51 Arr Adopted Flag
Rule10B51ArrAdoptedFlag
true
bolt Trd Arr Adoption Date
TrdArrAdoptionDate
May 19, 2023
bolt Trd Arr Termination Date
TrdArrTerminationDate
May 19, 2023
CY2023Q2 bolt Trd Arr Securities Agg Avail Amt
TrdArrSecuritiesAggAvailAmt
277083

Files In Submission

Name View Source Status
0000950170-23-039061-index-headers.html Edgar Link pending
0000950170-23-039061-index.html Edgar Link pending
0000950170-23-039061.txt Edgar Link pending
0000950170-23-039061-xbrl.zip Edgar Link pending
bolt-20230630.htm Edgar Link pending
bolt-20230630.xsd Edgar Link pending
bolt-ex31_1.htm Edgar Link pending
bolt-ex31_2.htm Edgar Link pending
bolt-ex32_1.htm Edgar Link pending
bolt-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
bolt-20230630_def.xml Edgar Link unprocessable
bolt-20230630_lab.xml Edgar Link unprocessable
bolt-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bolt-20230630_htm.xml Edgar Link completed
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bolt-20230630_cal.xml Edgar Link unprocessable